Pfizer (NYSE:PFE) announces positive results from a Phase 3 clinical trial, JADE Mono-1, evaluating orally available JAK1 inhibitor abrocitinib (PF-04965842) in patients at least 12 years old with severe atopic dermatitis (AD).
The study met the co-primary endpoints of statistically valid proportions of patients in the treatment groups achieving clear or almost clear skin and at least a two-point improvement in IGA score from baseline at week 12 and/or at least a 75% improvement in EASI score from baseline at week 12, compared to placebo. Key secondary endpoints were also met.
No new safety signals were observed.
Detailed results will be submitted for presentation at a future medical conference. Additional data from another study in the JADE program will be available later this year.
Subscribe for full text news in your inbox